Navigation Links
CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted to inform you about the upcoming scientific presentations of its novel immunotherapeutic CYT003-QbG10 to treat allergic diseases. Recently, positive clinical results for CYT003-QbG10 were obtained and will be presented in different sessions at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI), taking place from June 9-13, 2007 in Göteborg, Sweden. The EAACI Congress has developed into one of the most important annual events in the field of Allergy in the world. For more information please visit ww.congrex.com/eaaci2007.

CYT003-QbG10 presentations at EAACI 2007: 1) Oral presentation of Abstract No. 146: Dust mite allergy - new treatment options. Dr. med. Thomas Kündig, Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland will present the CYT003-QbG10 study findings relating to house dust mite allergy on Tuesday, June 12, 2007; Oral Abstract Session 26 - Novel developments in basic allergology; 3.30 - 5.00 pm (CET).

2) Poster presentation of Abstract No. 183: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy. Presentation is on Sunday, June 10, 2007; Poster Discussion Session 1 - Immunotherapy; 10.00 - 12.00 am (CET).

3) Poster presentation of Abstract No. 714: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy. Presentation is on Sunday, June 10, 2007; Poster Session - Allergen SIT IV; 12.00 -1.30 pm (CET).

Background: CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb f illed with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an "allergic" Th2 type immune response. An earlier, open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of allergic rhinitis and atopic dermatitis.

Please feel free to contact us at the address below should you wish to receive further information, address questions, or arrange meetings with Cytos Biotechnology directly.

With best regards,

Claudine Blaser

For more information please contact:

Claudine Blaser, PhD Director Corporate Communications Cytos Biotechnology AG Wagistrasse 25, Postfach CH-8952 Schlieren (Zurich) Tel. +41 44 733 47 20 Fax. +41 44 733 47 18 e-mail: claudine.blaser@cytos.com www.cytos.com


'"/>




Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
5. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
6. Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema
7. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
8. Data to be presented at AAN Meeting -Study results of drug candidate for MS
9. Data supporting three Antisoma programmes presented at AACR
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Walgreens has ... across 39 states and Washington, D.C. ... a move that was commended by shareholder advocacy organization As ... at As You Sow. "Many people hold on to unneeded ... which can have tragic consequences." --> Conrad ...
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
Breaking Medicine Technology:
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... Boca Raton, FL (PRWEB) , ... February 12, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – hosted over 250 members of South Florida’s philanthropic community at ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... the life cycle of pharmaceutical products, garnering increased attention from all stakeholders in ...
(Date:2/12/2016)... ... 2016 , ... As a former television executive, owner Tal Rabinowitz knows how ... to decompress, Rabinowitz found herself drawn to a casual meditation class while working at ... life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and ... the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for ... Forum and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, ...
Breaking Medicine News(10 mins):